Across TCGA pan-cancer cohorts, OR4A5 Mutation is linked to patient survival in 5 of 34 cancer types, making it the most broadly survival-associated OR4A5 data layer compared with 3 for mass-spec protein.
The strongest signal is observed in thyroid carcinoma (THCA), where higher OR4A5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR4A5 expression acts as an unfavorable survival marker.
THCA, SCLC, and ESCA are the cancer types where OR4A5 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.